IPP Bureau
EU unveils draft guidance to fast-track clinical trials during public health emergencies
By IPP Bureau - March 09, 2026
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial
By IPP Bureau - March 09, 2026
DiaMedica said it plans to launch the trial later in 2026
SEQSTER launches 1-Click DataLake, unlocking real-world health data from 150M+ patients
By IPP Bureau - March 09, 2026
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
Lupin receives two observations from USFDA for Ankleshwar facility
By IPP Bureau - March 09, 2026
The company will address the observations and respond to the U.S. FDA within the stipulated timeframe
Roche’s Gazyva shows breakthrough results in Lupus phase III trial
By IPP Bureau - March 07, 2026
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
FDA nod to groundbreaking combo therapy for relapsed multiple myeloma
By IPP Bureau - March 07, 2026
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
Roche’s experimental obesity drug shows strong weight-loss results in mid-stage trial
By IPP Bureau - March 07, 2026
The company announced positive topline data from the Phase II ZUPREME-1 trial
Evogene narrows focus to AI-driven molecule discovery after major strategic overhaul
By IPP Bureau - March 07, 2026
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026
By IPP Bureau - March 07, 2026
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Lonza to set up Global Capability Centre in Hyderabad
By IPP Bureau - March 06, 2026
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
Merck delivers resilient 2025 performance despite global headwinds
By IPP Bureau - March 06, 2026
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
CordenPharma expands boulder presence with 64,000-Sq-Ft Lease at BioMed Realty’s Flatiron Park
By IPP Bureau - March 06, 2026
The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant
argenx reports breakthrough Phase 3 results for VYVGART in ocular myasthenia gravis
By IPP Bureau - March 06, 2026
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
Sea Urchin spines inspire breakthrough sensor that detects water flow instantly
By IPP Bureau - March 06, 2026
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
